Navigation Links
Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
Date:5/2/2012

urnal of Medicine in December 2010 (n engl j med 363;26).

About XARELTO® (rivaroxaban)
XARELTO® belongs to a group of medicines called anticoagulants, and works by blocking the blood clotting Factor Xa, thereby reducing the tendency to form clots. In the U.S., XARELTO® is indicated to reduce the risk of blood clots in the legs and lungs of people who have just had knee or hip replacement surgery, and to reduce the risk of stroke and other complications related to migrating blood clots in people with atrial fibrillation not caused by a heart valve problem. There is limited information on how XARELTO® compares to a medicine called warfarin in reducing the risk of stroke when the blood levels of warfarin are well-controlled. The blood levels of warfarin often vary in patients.

The extensive program of clinical trials evaluating rivaroxaban makes the compound the most studied oral, Factor Xa inhibitor in the world today. Rivaroxaban is being developed jointly by Janssen Research & Development, LLC and Bayer HealthCare. U.S. marketing rights for XARELTO® are held by Janssen Pharmaceuticals, Inc.

About Janssen Research & Development, LLC
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Janssen Research & Development, LLC and Janssen Pharmaceuticals, Inc., are part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Please visit www.janssenrnd.com for more information.

Important Safety Informat
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Janssen Research & Development, LLC Opens JANSSEN LABS at San Diego
2. Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
3. Record Breaking $327 Million Verdict Upheld in Janssen Case and Request for New Trial Denied
4. Dr. Paul Janssen Award for Biomedical Research Issues Call for Nominations
5. Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc.
6. Janssen Pharmaceuticals, Inc. Launches Online Tools on PrescribeResponsibly.com
7. Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest Ortho Dermatologics Division
8. Dr. Napoleone Ferrara Wins 2011 Dr. Paul Janssen Award for Biomedical Research
9. Janssen Products, LP Modifies Prescribing Information for PROCRIT® (Epoetin alfa) in Chronic Kidney Disease
10. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets
11. Record Breaking $327 Million Verdict Announced in Janssen Case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... STAMFORD, Conn. , April 20, 2015 /PRNewswire/ ... announced that Alan Butcher has joined ... & Business Development. Alan will have responsibility for ... commercial, near-commercial, and development-stage products that would benefit ... bringing aboard a proven leader," said Purdue President ...
(Date:4/20/2015)... , April 20, 2015 Stand Up To Cancer (SU2C) ... a $20 million Dream Team to attack the number one ... Annual Meeting of the American Association for Cancer Research (AACR), ... 221,000 people in the United States ... and 158,040 will die from it, making lung cancer the ...
(Date:4/20/2015)... SAN DIEGO , April 20, 2015 /PRNewswire/ ... biotechnology company developing novel oncology and drug-delivery therapies, ... at the American Association for Cancer Research (AACR) ... interim results of its randomized Phase 2 study ... the annual meeting of the American Society of ...
Breaking Medicine Technology:Purdue Pharma Names J. Alan Butcher Senior Vice President of Licensing & Business Development 2New SU2C-American Cancer Society Lung Cancer Dream Team Announced 2New SU2C-American Cancer Society Lung Cancer Dream Team Announced 3New SU2C-American Cancer Society Lung Cancer Dream Team Announced 4New SU2C-American Cancer Society Lung Cancer Dream Team Announced 5New SU2C-American Cancer Society Lung Cancer Dream Team Announced 6Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 2Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 3Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 4Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 5
... Company,s TPM Drug Delivery Technology Demonstrates Substantial Increase ... Leading Marketed Product -, MELBOURNE, Australia, April ... OTCQX: PPGNY) today,announced positive results of a pre-clinical ... for the targeted delivery of lidocaine,demonstrating increased efficacy ...
... Immunologics, Inc. ("QI"),announces the commencement of a Phase ... of a novel anti-cancer vaccine/immunotherapy that will,be used ... Patients accepted,into the study have previously failed to ... chemotherapy. QI has commissioned,the study to be done ...
Cached Medicine Technology:Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine 2Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine 3Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine 4Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas 2Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas 3
(Date:4/20/2015)... Genuine fat loss results can seem virtually ... in the past. But what failed dieters and gym-goers don’t ... guaranteed by adhering to five simple principles. , 1. Nutrition, ... many hours one spends working at the gym, a poor ... a nutritional mean plan does not mean starvation, calorie counting ...
(Date:4/20/2015)... 20, 2015 Today the members ... Research Fund-Ovarian Cancer National Alliance-National Ovarian Cancer Coalition ... Team will focus on “DNA Repair Therapies for ... identified DNA repair as a common weakness in ... and early detection of ovarian cancer by developing ...
(Date:4/20/2015)... Westchester County, New York (PRWEB) April 20, 2015 ... that the Centers for Medicare & Medicaid Services introduced ... of their HCAHPS (Hospital Consumer Assessment of Healthcare Providers ... This national survey asks patients about their experiences during ... current survey results from July 1, 2013 through June ...
(Date:4/20/2015)... The buttocks tend to become sore and ... from Longmont, Colo., decided that there needed to be ... use, compact and ideal for travelers and truck drivers, ... from becoming sore during travel via airplanes and vehicles. ... blood circulation, which helps to avoid blood clots. , ...
(Date:4/20/2015)... Columbia (PRWEB) April 20, 2015 Cannabix ... a hand-held Cannabix Marijuana Breathalyzer for law enforcement and ... the first publicly available images of its marijuana breathalyzer ... Cannabix Marijuana Breathalyzer. Media files and video that show ... for online viewing at cannabixtechnologies.com . , The ...
Breaking Medicine News(10 mins):Health News:Guarantee Fat Loss Results With 5 Easy Tips 2Health News:Guarantee Fat Loss Results With 5 Easy Tips 3Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 2Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 3Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 4Health News:Northern Westchester Hospital Named a 5-Star Hospital In Medicare's Patient Satisfaction Rating 2Health News:Northern Westchester Hospital Named a 5-Star Hospital In Medicare's Patient Satisfaction Rating 3Health News:Cannabix Technologies Inc. Releases New Images of Marijuana Breathalyzer Prototype 2Health News:Cannabix Technologies Inc. Releases New Images of Marijuana Breathalyzer Prototype 3Health News:Cannabix Technologies Inc. Releases New Images of Marijuana Breathalyzer Prototype 4
... (Nasdaq: MLNM ) today announced that its ... (ASH) meeting will be,webcast live and may be ... website, http://www.millennium.com ., (Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO ... by Millennium senior management as,well as clinical investigators ...
... UNAIDS/WHO AIDS epidemic update released last week has revised the ... of the estimate for India to 2.5 million people living ... official estimate of 5.7 million people. This revision is based ... in India. , A commentary published in the Lancet on ...
... resolve ongoing debate , MONDAY, Dec. 3 (HealthDay News) ... B and the risk of developing multiple sclerosis (MS) in ... studies have investigated a possible association between the hepatitis B ... of increased short- or long-term risk of MS. However, ...
... St. Louis, Dec. 3, 2007 Psychiatry researchers at Washington ... a clinical diagnosis of alcohol dependence in young adults is ... "Some participants in the study reported 50 or 100 partners, ... that the more sex partners you have, the more likely ...
... Tucson Marathon Runners, PLEASANT GROVE, Utah, Dec. 3 ... inflammation and pain, but at the same time,worry about ... University and Vanderbilt University, published in,Medicine & Science in ... be unhealthy in the long term. The practice leads ...
... The American Association,of Colleges of Nursing (AACN) today ... entry-level baccalaureate nursing programs,increased by 4.98 percent from ... year of enrollment growth, the rate at which ... has declined sharply since 2003,when enrollment was up ...
Cached Medicine News:Health News:Millennium Pharmaceuticals Announces Webcast of American Society of Hematology Investor Event 2Health News:Implications of the new HIV estimate for India 2Health News:No Link Between Hepatitis B Shot, MS: Study 2Health News:Heavy drinking, conduct disorder linked to high-risk sexual behavior 2Health News:Heavy drinking, conduct disorder linked to high-risk sexual behavior 3Health News:Marathoners Share Tom Brady and LaDainian Tomlinson Pain Relief Affinity 2Health News:Enrollment Growth Slows at U.S. Nursing Colleges and Universities in 2007 Despite Calls for More Registered Nurses 2Health News:Enrollment Growth Slows at U.S. Nursing Colleges and Universities in 2007 Despite Calls for More Registered Nurses 3Health News:Enrollment Growth Slows at U.S. Nursing Colleges and Universities in 2007 Despite Calls for More Registered Nurses 4Health News:Enrollment Growth Slows at U.S. Nursing Colleges and Universities in 2007 Despite Calls for More Registered Nurses 5
Bio-Rad's Liquichek™ D-dimer Control provides the laboratory with a liquid, trilevel, human plasma based control for the monitoring of D-dimer testing on most automated coagulation, chemistry a...
Lyphochek Coagulation Control is a human plasma control for monitoring the performance of routine coagulation tests. It has an extended reconstituted stability which helps reduce waste and save money...
Lyphochek Diabetes Control is a human whole blood based product used to monitor hemoglobin fractions associated with diabetes, including Hemoglobins A1, A1C, F and Total Glycated Hemoglobin....
... Liquichek Qualitative Urine Toxicology Control is a ... rapid urine drug screen panels, including Point ... test kits like Bio-Rad TOX/See, Biosite Triage ... qualitative results (+/) for popular kits and ...
Medicine Products: